Search
SOLACI Congress
HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

Anti-Lipid Therapy in PCI Patients: Monotherapy with Statins or Combination?

According to several studies, in patients with high-risk atherosclerotic disease, such as those affected by coronary artery...
solaci -
Learn More
Acute coronary syndromes

Substudy TALOS AMI: from Ticagrelor to Clopidogrel in Patients with High Risk of Bleeding and AMI

The preference for the use of potent P2Y12 inhibitors such as ticagrelor and prasugrel in patients with...
solaci -
Learn More
Acute coronary syndromes

ESC 2023 | Anticoagulation After Primary PCI in STEMI Patients

The empirical prescription of anticoagulants after percutaneous coronary intervention (PCI), also know as post-procedural anticoagulation (PPA), is...
solaci -
Learn More
Antiplatelet

ESC 2023 | Extended Monotherapy with Clopidogrel vs. DAPT in High-Risk Patients

An increasing number of patients currently present both an elevated ischemic risk and hemorrhagic risk. This means...
solaci -
Learn More
Antiplatelet

ESC 2023 | STOPDAPT-3 

Short Dual antiplatelet therapy (DAPT), one to three months, followed by P2Y12 inhibitor monotherapy has been shown...
solaci -
Learn More
Chronic Coronary Syndromes

MACT Study: Monotherapy with P2Y12 Inhibitor Associated with Colchicine after Acute Coronary Syndrome

Dual antiplatelet therapy (DAPT) is the current standard for preventing thrombotic events in high-risk patients with coronary...
solaci -
Learn More
Antiplatelet

SOLACI-SBHCI 2023 | Patient-centered Selection Anti-platelet Treatment for ACS-PCI Patients: Real World Evidence of Prasugrel – Dr. Roxana Mehran

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Roxana...
solaci -
Learn More
Antiplatelet

SOLACI-SBHCI 2023 | Is very short DAPT safe in HBR patients undergoing complex PCI – Dr. Marco Valgimigli

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Marco...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

ACC-2025 Congress Second Day Key Studies

Dr. Juan Manuel Pérez - 0
BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Dr. Omar Tupayachi - 0
Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

Dr. Omar Tupayachi - 0
The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

Institutional News

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Uruguay Sessions 2025 | Young Interventional Cardiologists Contest

solaci - 0
Call for Case Submission LI SOLACI Regional Sessions – 16° Southern Cone  It is with great pleasure that we hereby invite all young Latin American cardiologists...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy